Pharma Surge

Pharma Surge

🇺🇸·18h agoResearch

NCT06875310: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Study type: INTERVENTIONAL. Phase: PHASE3.

Publisher

C
ClinicalTrials.gov

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
ClinicalTrials.gov
Region
USA
Scope
Research
Published
July 8, 2026
Language
EN

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Study type: INTERVENTIONAL. Phase: PHASE3.

Source route

Continue on clinicaltrials.gov

Leave the platform to read the original full article on the publisher site.

Source: ClinicalTrials.gov

Scope: Research

Open original article
NCT06875310: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Pharma Surge